CoreFirst Bank & Trust Cuts Position in Bristol-Myers Squibb (NYSE:BMY)

CoreFirst Bank & Trust lowered its position in Bristol-Myers Squibb (NYSE:BMYFree Report) by 4.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,380 shares of the biopharmaceutical company’s stock after selling 627 shares during the quarter. CoreFirst Bank & Trust’s holdings in Bristol-Myers Squibb were worth $635,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Westside Investment Management Inc. lifted its holdings in shares of Bristol-Myers Squibb by 2.9% during the 4th quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock valued at $367,000 after buying an additional 204 shares during the last quarter. Fulton Breakefield Broenniman LLC lifted its stake in Bristol-Myers Squibb by 4.6% in the fourth quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 209 shares during the last quarter. Chapin Davis Inc. increased its stake in shares of Bristol-Myers Squibb by 1.2% during the 4th quarter. Chapin Davis Inc. now owns 18,385 shares of the biopharmaceutical company’s stock worth $943,000 after purchasing an additional 214 shares during the last quarter. Tilson Financial Group Inc. raised its holdings in shares of Bristol-Myers Squibb by 3.7% during the 4th quarter. Tilson Financial Group Inc. now owns 6,258 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 221 shares in the last quarter. Finally, Highland Capital Management LLC raised its holdings in shares of Bristol-Myers Squibb by 0.3% during the 4th quarter. Highland Capital Management LLC now owns 72,431 shares of the biopharmaceutical company’s stock valued at $3,716,000 after purchasing an additional 225 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on BMY shares. BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. Barclays decreased their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Finally, William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $60.00.

Check Out Our Latest Stock Analysis on Bristol-Myers Squibb

Bristol-Myers Squibb Trading Down 0.6 %

NYSE:BMY traded down $0.23 during mid-day trading on Monday, hitting $40.97. The company had a trading volume of 18,122,740 shares, compared to its average volume of 15,447,579. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. Bristol-Myers Squibb has a fifty-two week low of $39.91 and a fifty-two week high of $66.38. The firm has a market cap of $83.05 billion, a P/E ratio of -13.22, a P/E/G ratio of 13.95 and a beta of 0.43. The business’s fifty day moving average is $44.30 and its two-hundred day moving average is $48.67.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same period last year, the business posted $2.05 earnings per share. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, research analysts expect that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Further Reading

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.